KalVista Pharmaceuticals (NASDAQ:KALV) has announced that Jeb Ledell has been appointed as chief operating officer (COO).
Mr. Ledell brings more than 20 years of leadership and operational excellence in the biotechnology industry to KalVista. He joins the company from AVEO Oncology, where he served as COO and oversaw AVEO’s operational strategy. Prior to AVEO, Mr. Ledell served as COO at Enzyvant Therapeutics, where he played a key role in the successful FDA approval of RETHYMIC.
“I am pleased to welcome Jeb to KalVista at this key time in our evolution. His extensive experience in leading teams and driving efficiency within companies like ours makes him a valued addition to the team as we continue to evolve into a commercial entity,” said Ben Palleiko, CEO of KalVista. “I am confident that his proven skills will help us to achieve our goal of delivering sebetralstat to help transform the lives of people living with hereditary angioedema.”
Mr. Ledell added, “I am excited to join the talented team at KalVista as the company prepares to launch sebetralstat on a global scale. I am eager to contribute my insights and experience to drive forward the company’s mission of delivering a transformative new therapy for those impacted by hereditary angioedema.”
